fbpx

Press Releases

ThermoGenesis Unveils Comprehensive Suite of Products and Services to Fight the Global COVID-19 Pandemic

RANCHO CORDOVA, Calif., Sept 2, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, along with its joint venture, ImmuneCyte, Inc. today announced plans to roll out a comprehensive diagnostic and therapeutic product line to fight the global COVID-19 pandemic. The multi-pronged … Continued

ThermoGenesis Holdings to Participate in Investor Conferences in September

RANCHO CORDOVA, Calif., Aug. 31, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO) a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced management’s participation in the following investor conferences in September.   September 1-4: LD Micro 500. Chris Xu, Ph.D., Chief Executive Officer of ThermoGenesis, will present … Continued

ThermoGenesis Enters Into Supply Agreement with New EUA Approved COVID-19 Antibody Test Manufacturer; Marketing to Begin on August 17, 2020

RANCHO CORDOVA, Calif., August 13, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced that on August 12, the Company entered into a supply agreement with BioHit Healthcare (Hefei) Co., Ltd. to market, under the ThermoGenesis brand, its SARS-CoV-2 IgM/IgG Antibody … Continued

ThermoGenesis Holdings to Delay Second Quarter 2020 Earnings Release and Conference Call Until Friday August 14, 2020

RANCHO CORDOVA, Calif., Aug. 11, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced it will delay its second quarter earnings release and conference call for the quarter ended June 30, 2020, previously scheduled for Wednesday, August 12, … Continued

ThermoGenesis Holdings to Announce Financial Results for the Second Quarter Ended June 30, 2020 and Provide a Corporate Strategic Update

Conference Call to be Held on August 12, 2020 RANCHO CORDOVA, Calif., August 5, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the second quarter ended June 30, 2020 … Continued

ThermoGenesis Announces Corning’s Commercial Launch of the X-SERIES® Cell Processing Products Developed by ThermoGenesis

Innovative Density Gradient Media-Free & Buoyancy-Activated Cell Sorting (BACS) Technologies Improve Manufacturing Efficiency and Yield of Cell & Gene-Therapy Products   RANCHO CORDOVA, Calif., June 23, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced today that, pursuant to its existing, … Continued

ThermoGenesis to Join Russell Microcap® Index

RANCHO CORDOVA, Calif., June 16, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced today that the Company is set to join the Russell Microcap® Index at the conclusion of the 2020 Russell indexes annual reconstitution, effective after the US market … Continued

ThermoGenesis Announces Filing of Patent Applications for Device that Improves the Accuracy of Lateral Flow Immunoassays (LFIA) in the Detection of COVID-19 Antibodies

RANCHO CORDOVA, Calif., June 11, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced today that the Company has filed patent applications for a point-of-care device which improves the speed and accuracy of lateral flow immunoassays (LFIA) to detect COVID-19 IgM … Continued

ThermoGenesis Announces That Results of ImmuneCyte’s Licensed Neutralizing Antibody Therapeutics for COVID-19 Were Published in bioRxiv

RANCHO CORDOVA, Calif., June 8, 2020 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced today that the Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, the research partner of ThermoGenesis’ joint venture, ImmuneCyte, Inc., published the … Continued

© 2020 ThermoGenesis Corp.
How may we help?